Association Between Sleep Quality, Musculoskeletal Pain and Physical and Psychosocial Well-Being Among Employees Working from Home
Life Sciences-Physiotherapy
DOI:
https://doi.org/10.22376/ijlpr.2023.13.SP1.L16-23Keywords:
Work From Home, COVID-19, Sleep Quality, Pain, Well-BeingAbstract
COVID-19 has perplexed the world into an unexpected state of affairs. With the implementation of nationwide lockdown, people have begun to ‘Work for Home’ in many employment sectors. Though the policy has managed to keep people safe from the devastating effects of the virus, it has, however, imposed most employees into a sedentary lifestyle. The current situation has resulted in disordered sleep, musculoskeletal pain, physical and psychosocial well-being decline due to irregular work hours, and mental health issues due to corona phobia. The current study aims to find the correlation between sleep duration, musculoskeletal pain, and physical and psychosocial well-being in employees working from home during the COVID-19 pandemic lockdown. One hundred fifty-three samples from the North India region were studied in a correlation study. Subjects working from home for at least one month or more and only due to COVID-19 lockdown were excluded, while those with any musculoskeletal, cardiovascular or neurological disorder were excluded. Questionnaires employed were Pittsburg Sleep Quality Index (PSQI) (for sleep quality), Chronic Pain Grade Questionnaire (CPGQ) (for pain intensity), and Short Form-12 (SF-12) Questionnaire (for physical and psychosocial well-being). Scores were calculated, and Pearson’s correlation was found. One hundred fifty-three samples (mean age= 32.73±5.55, mean height=167±9.22, mean weight=67.2±13.7, mean BMI=23.9±3.97) were evaluated, which revealed a higher negative correlation coefficient value between MSK pain intensity and PCS value (-0.535) describing that the pain increased with deterioration in sleep, and sleep quality and MCS value (-0.423) stating that the psychosocial well-being worsened with the decline in sleep quality; while a highly positive correlation was established with the sleep quality and pain intensity scores (0.420) depicting that pain degraded the physical well-being. A weak correlation was reported in the relationship between the intensity of MSK pain with sleep quality (-0.218) and PCS score (-0.323), suggesting no significant impact (significant at the 0.01 level (2-tailed). A significant correlation has been established between sleep quality, the intensity of musculoskeletal pain, and the physical and psychosocial well-being of employees working from home during the COVID-19 pandemic lockdown.
References
Casteel DA. Antimalarial agents. In: Burger’s medicinal chemistry and drug discovery. 6th ed. Volume 5: Chemotherapeutic Agents. New York: A John Wiley & Sons, Inc. [publication]; 2003: 920-31.
White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis. 2008;46(2):172-3. doi: 10.1086/524889, PMID 18171246.
Available from: http://www.who.int assessed on 23.05.2022.
Jagannathan P, Kakuru A. Malaria in 2022: increasing challenges, cautious optimism. Nat Commun. 2022;13(1):2678. doi: 10.1038/s41467-022-30133-w, PMID 35562368.
Robert A, Benoit-Vical F, Dechy-Cabaret O, Meunier B. From classical antimalarial drugs to new compounds based on the mechanism of action of artemisinin. Pure Appl Chem. 2001;73(7):1173-88. doi: 10.1351/pac200173071173.
O’Neill PM, Bray PG, Hawley SR, Ward SA, Park BK. 4-aminoquinolines: past, present and future: a chemical perspective. Pharmacol Ther. 1998;77(1):29-58. doi: 10.1016/s0163-7258(97)00084-3, PMID 9500158.
Bloland PB. Drug resistance in malaria. Geneva: WHO. World Health Organization/CDS/CSR/DRS/2001.4; 2001. p. 1-20.
Chiang PK, Bujnicki JM, Su X, Lanar DE. Malaria: therapy, genes and vaccines. Curr Mol Med. 2006;6(3):309-26. doi: 10.2174/156652406776894545, PMID 16712477.
Cambia Institute. The lens patent data set. Version 8.0.14 [cited Mar 30 2022]. Available from: https://www.lens.org.
European Patent Office. Espacenet glossary. Version 1.24.1 [cited Mar 5 2022]. Available from: https://worldwide.espacenet.com/patent.
World Intellectual Property Organization. IPC publication. Version 2022.01 [cited Mar 5 2022]. Available from: https://www.wipo.int/classifications/ipc/en/.
World Intellectual Property Organization. Guide to the international patent classification (IPC) [cited Mar 5 2022]. Available from: https://www.wipo.int/edocs/pubdocs/en/wipo_guide_ipc_2020.pdf.
International Patent Classification (IPC) [cited Mar 10 2022]. Available from: https://ipcpub.wipo.int/.
PCT glossary, World Intellectual Property Organization. Guide to the international patent classification (IPC) [cited Mar 5 2022]. Available from: https://www.wipo.int/pct/en/texts/glossary.html.
Medicines for Malaria Venture. MMV – Company Profile [cited Jan 05 2022]. Available from: https://www.mmv.org/.
Evelo Biosciences INC. Company Profile [cited Mar 05 2022]. Available from: https://evelobio.com/.
World Intellectual Property Organization. What is intellectual property? Frequently asked questions: patents [cited Mar 28 2022]. Available from: https://www.wipo.int/patents/en/faq_patents.html.
United States Patent and. Trademark office. Manual of patent examining procedure: ownership/assignability of patents and applications [cited Mar 28 2022]. Available from: https://www.uspto.gov/web/offices/pac/mpep/mpep-0300.html.
World Intellectual Property Organization. Legal status [cited Feb 22 2022]. Available from: https://www.wipo.int/edocs/mdocs/aspac/en/wipo_it_ip_tyo_17/wipo_it_ip_tyo_17_t6.pdf.
WIPO intellectual property handbook [cited Mar 10 2022]. Available from: https://www.wipo.int/edocs/pubdocs/en/wipo_pub_489.pdf.
Riscoe MK, KJX, Winter RW, Hinrichs DJ, Smilkstein MJ, Nilsen A et al. Compounds having antiparasitic or anti-infectious activity. Patent US9206131B2. USA; December 08, 2015.
Peyton DH, Burgess S. Quinoline derivatives and uses thereof. Patent US9493420 B2. USA; November 15, 2016.
Higuchi T, Kato N, Umezawa N. Compound having antimalarial Activity, and antimalarial Drug. Patent WO2015/133280A. Vol. 1. Seattle: Pet Care Trust; September 11, 2015.
Chakrabarti D, Yuan Y, Huang G, Solano C. Antimalarial compounds. Patent WO2020/206252A. Vol. 1. Seattle: Pet Care Trust; October 08, 2020.
Mhaske SB, Mahajan JP, Dhanasekaran S. Antimalarial heterocyclic compounds and a process for the preparation thereof. Patent US2021/0087187A. Vol. 1. USA; March 25, 2021.
Mhaske SB, Lande JR. Pyrroloquinoline alkaloids as antimalarial agents and process for the preparation thereof. Patent US2015/0336947A. Vol. 1. USA; December 08, 2016.
Geiger WE, Lam K, Bergman LW. Use of Cymanquine compounds as antimalarial agents. Patent US2018/0214457A. Vol. 1. USA; August 02, 2018.
Guy RK, Hammill JT, Floyd D, Burrows J, Brand S. New antimalarial agents. Europe. Patent EP3892332A1. 2021;13 October.
Guy RK, Zhu F, Guiguemde WA, Floyd D, Knapp S, Stein P et al. Substituted 2-Alkyl-1-Oxo-N-Phenyl-3-Heteroaryl-1,2,3,4-Tetrahydroisoquinoline-4-Carboxamides for antimalarial therapies. Patent US9416124 B2. USA; August 16, 2016.
Fasan R, Zhang K-D. Artemisinin derivatives, methods for their preparation and their Useas antimalarial agents. Patent EP 3450549. Europe. March 06, 2019;A1.
Yang D, Liu J, Fan L, Zhang S, Tang X. Application of dihydroartemisinin derivative of Antimalarial Drug. Patent CN110448552 A. China; November 15, 2019.
Yang D, Zhang S, Fan L, Liu J, Tang X, Meng R. Thio ether, sulfoxide and sulfone derivatives of dihydroartemisinin, and applications thereof. Patent CN110642869 A. China; January 03, 2020.
Li X, Si M. Artesunate heparin derivative as well as pharmaceutical composition and application thereof. Patent CN109481692A. China; March 19, 2019.
Bhattacharya A, Aratikatla EK, Malhotra P, Mohmmed A. Novel antimalarial compounds, process for preparation and their use for drug resistant malaria. Patent CN112585142A. China; March 30, 2021.
Davioud-Charvet E, Lanfranchi DA, Johann L, Williams DL, Cesar RE. Total synthesis of redox-active 1.4-naphthoquinones and their metabolites and their therapeutic use as antimalarial and schistomicidal agents. Patent US9409879 B2. USA; August 09, 2016.
Davioud-Charvet E, Muller T, Bauer H, Schirmer RH. 1,4-Naphthoquinones derivatives and therapeutic use thereof. Patent US9090549 B2. USA; July 28, 2015.
Kalyanaraman B, Cheng G, Hardy Micael J. Mitochondria-targeted atovaquone: A more potent and more effective antitumor, antimicrobial, and antimalarial Drug. Patent WO2021/081500A. Vol. 1. Seattle: Pet Care Trust; April 29, 2021.
Vennerstrom JL, Charman SA. New antimalarial agent. Patent US2020/0377483A. Vol. 1. USA; December 03, 2020.
Vennerstrom JL, Dong Y, Charman SA, Wittlin S, Chollet J, Creek DJ et al. Dispiro 1,2,4-trioxolane antimalarials. Patent CA2702256C. Canada; September 26, 2017.
Tarnchompoo B, Chitnumsub P, Kamchonwongpaisan S, Shaw PJ, Rattanajak R, Poen S et al. Antifolate antimalarials with dual-binding modes and their preparation. Patent US9000003B2. USA; April 07, 2019.
Phillips M, Charman SA, Rathod PK, Matthews D, Waterson D. New substituted triazolopyrimidines as antimalarial agents. Patent WO2016/151521. Vol. A1. Seattle: Pet Care Trust; September 29, 2016.
Khan TA, Cumming JN, Olsen DB, Boddey JA, Cowman AF, Sleebs BE. N3-substituted Iminopyrimidinones as antimalarial agents. Patent WO2017/142825. Vol. A2. Seattle: Pet Care Trust; August 24, 2017.
Waterson D, Witty MJ, Chibale KY, Street L, Gonzalez CD, Paquet T. Antimalarial agents. Patent EP3118198A1. Europe; January 18, 2017.
Donald TWJ, Rainer PP, Hong TC. Compounds having antimalarial Activity. Patent WO2020/263191. Vol. A1. Seattle: Pet Care Trust; December 30, 2020.
Younis Y, Chibale K, Witty MJ, Waterson D. Antimalarial agents. Patent US9266842B2. USA; February 23, 2016.
Jiang L, Haung Z. Novel high-efficiency antimalarial Drug, quisinostat. Patent WO2017/143964. Vol. A1. Seattle: Pet Care Trust; August 31, 2017.
Wada A, Hayase H, Watanabe N, Osada H, Shimizu T, Wierzba K. Antimalarial agent. Patent US2019/0054074A. Vol. 1. USA; February 21, 2019.
Wada A, Hayase H, Watanabe N, Osada H, Shimizu T, Wierzba K. Antimalarial agent. Patent EP3093020A1. Europe; November 16, 2016.
Chatterjee AK, Nagle AS, Paraselli P, Kondreddi RR, Leong SY, Mishra PK et al. Compounds and Compositionsa or the treatment of parasitic diseases. Patent US9926314 B2. USA; March 27, 2018.
Witty MJ, Hardick D. New antimalarial agents. Patent EP2526090B1. Europe; August 19, 2015.
Horii T, Suzuki S, Roupany AJA, Mui JJB, Lewis-Marshall JP, Devan FA et al. Novel antimalarial agent containing heterocyclic compound. Patent WO2021/149692A. Vol. 1. Seattle: Pet Care Trust; July 29, 2021.
Freitas Da Costa MS, Monginho BMDF, De Jesus RPPMF, Mendes VMI, Mendes FPE, Martins CCS. Antimalarial agent, methods and uses thereof. Patent WO2021/191882. Vol. A1. Seattle: Pet Care Trust; September 30, 2021.
Heffernan GD, Jacobus DP, Schiehser GA, Shieh HM, ZW. Aryl derivatives and uses thereof. Patent US8962657 B2. USA. Vol. 24(February); 2015.
Sullivan D, Kaludov N, Liu Y, Martinov M. Macrolide compounds and their use in liver stage malaria and related disease. Patent US2019/0091216. Vol. A1. USA; February 21, 2019.
Havaldar FH, Dabholkar BV, Mule GB. Preparation of novel deferasirox analogues for antimalarial activity. Patent WO2016/203488. Vol. A1. Seattle: Pet Care Trust; December 22, 2016.
Sciotti RJ, Reichard GA, Pannone KM, Zottig VE. Substituted triazines for malaria treatment and chemoprophylaxis. Patent US2015/0210652. Vol. A1. USA; July 30, 2015.
Nardella F, Halby L, Haitham H, Menard D, Scherf A, Arimondo PB. Trilobine derivatives and their use thereof in the treatment of malaria. Patent EP 3907227. Europe. November 10, 2021;A1.
Luckhart S, Glennon EKK. Use of abscisic acid for the prevention and treatment of malaria. Patent US10154974 B. USA; December 18, 2018.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Kanishka, Kumar Manish, Sumit Tewatia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
